Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Non-muscle-invasive bladder cancer, drawn from the whole corpus: 41 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Recurrent BCG shortages.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Predicting who will progress to muscle invasion.
The burden and cost of lifelong cystoscopy.
Comparing the new bladder-sparing options with each other and with cystectomy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 18 changes by month →FDA approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
When this page itself was last checked or edited.
BCG-unresponsive NMIBC with CIS; 28 May 2026 (conditional)
BCG-unresponsive NMIBC with CIS, with BCG; 16 Feb 2026 (conditional)
FDA approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
BCG-unresponsive high-risk NMIBC with CIS, with or without papillary tumours